Insights & Resources
Optimizing Outsourced Operations in Life Sciences
Our infographic, created in conjunction with Citeline, explores current partnership preferences among life sciences organizations, along with onshoring trends that have greatly affected the industry, using data from a recent Citeline survey of senior-level executives in the space.
Using Global Onshoring Trends to Identify Industry Gaps in Life Sciences
Our whitepaper, created in conjunction with Citeline, provides insights into how leaders in the industry are using the capabilities of contract development and manufacturing organizations (CDMOs) and onshoring to solve major challenges and advance their development processes.
Extractables & Leachables: Solutions for Risk Management and Analytical Testing
Extractables and leachables (“E&L”) studies are an essential component of regulatory filing to demonstrate product safety. Depending on the container-closure system or medical device being evaluated, E&L studies can be very complex. Choosing a CDMO with expertise is critical to successful delivery of robust E&L data that you can trust.
Design of Experiments Approach to Enabling Studies for Process Validation
Process validation is a key step in preparing for commercial active pharmaceutical ingredient (API) production, requiring a significant depth of knowledge and data related to the manufacturing process. Read our whitepaper to learn how Cambrex applied process improvement methodology to the process validation step in order to reduce costs for our client.
Progressing Drug Therapies to Market: The Criticality of Analytical Testing Robustness
Rigorous, effective analytical testing is key in the drug development lifecycle. Because this testing is used to verify control of drug chemistry, it can help identify barriers that prevent movement to the next phase in the development process. That’s why it’s critical to have efficient, accurate and high-quality analytical support for your testing requirements.
Adapting CDMO Capabilities to Support the Development and Commercialization of Orphan Drugs and Novel Therapies
As more novel therapies and orphan drugs fill the drug development pipeline, small-scale CDMO capabilities have become an increasingly common need for sponsors developing and commercializing new drug entities.
Navigating New Regulations in Biobanking for Clinical Studies and Research Projects
Join us to hear Prof. Jonathan Douxfils, CEO and Co-Founder of QUALIblood, as he explains the latest regulations in biobanking and their impact on clinical studies, what changes researchers may need to implement in their projects, and the potential challenges in complying with these new regulations.
Talk to one of our experts
Our scientists specialize in making connections. Start a conversation today and see what it’s like to work with a collaborative CDMO.Get in touch with an expert